ArticleEuropean journal of nuclear medicine and molecular imaging2019
FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma.
Article in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed.
- PET|MR Open Source Radiomics Models for Treatment Outcome Prediction in Recurrent GBM.Cancers · 2026Article
- Distinguishing true progression from treatment effects in glioblastoma: a practical, evidence-graded imaging framework for the multidisciplinary team.Journal of neuro-oncology · 2026Review
- Multimodal PET-MR segmentation for glioblastoma: complementarity for treatment planning and recurrence definition.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Cutting-edge approaches in pet imaging for gliomas: current applications for neurooncologists and the path to theranostic breakthroughs.European journal of nuclear medicine and molecular imaging · 2026Review
- [Journal of neuro-oncology · 2026Article
- Review
- Spatial tumour characteristics as an indirect marker of metabolic dysregulation: evaluation for non-invasive IDH-genotyping of glioma using hybrid [18 F]FET-PET/MRI.European journal of nuclear medicine and molecular imaging · 2026Article
- A New Fluorine-18-Fluoroethyltyrosine Positron-Emission-Tomography/Magnetic-Resonance-Based Tumor Resection Plan Improved the Prognosis of Glioblastoma Patients. A Multicenter Validated Study.Research (Washington, D.C.) · 2026Article
- Clinical Utility of Amino Acid PET-MRI in Children with CNS Neoplasms: A Territory-Wide Study from Hong Kong.Cancers · 2025Article
- Diagnosis of treatment-related changes in children and adolescents with brain and spinal tumors: a cost-effectiveness analysis using MRI and [18 F]FET PET.European journal of nuclear medicine and molecular imaging · 2025Article
- Brain Tumor Characterization Using Multiple MR Parameters From Multi-Contrast EPI With Keyhole (GE-SE EPIK) Including Oxygen Extraction Fraction: A Comparison to O-(2-[18F]Fluoroethyl)-L-Tyrosine (FET) Positron Emission Tomography.Journal of magnetic resonance imaging : JMRI · 2025Article
- Interobserver ground-truth variability limits performance of automated glioblastoma segmentation on [EJNMMI physics · 2025Article
- Comparison ofClinical and translational radiation oncology · 2025Article
- Article
- Measurable disease as baseline criterion for response assessment in glioblastoma: A comparison of PET -based (PET RANO 1.0) and MRI-based (RANO) assessments.Neuro-oncology · 2025Article
- Advances in Glioblastoma Diagnosis: Integrating Genetics, Noninvasive Sampling, and Advanced Imaging.Cancers · 2025Review
- The role of FET-PET in patient selection and response assessment for reirradiation in recurrent glioblastoma.Frontiers in oncology · 2025Review
- Comparison of 5-aminolevulinic acid and MMP-14 targeted peptide probes in preclinical models of GBM.Theranostics · 2025Article
- Advanced diffusion MRI provides evidence for altered axonal microstructure and gradual peritumoral infiltration in GBM in comparison to brain metastases.Clinical neuroradiology · 2024Article
- Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: A report of the PET/RANO group.Neuro-oncology · 2024Review
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAreas of contrast enhancement (CE) on MRI are usually the target for resection or radiotherapy target volume definition in glioblastomas. However, the solid tumour mass may extend beyond areas of CE. Amino acid PET can detect parts of the tumour that show no CE. We systematically investigated tumour volumes delineated by amino acid PET and MRI in patients with newly diagnosed, untreated glioblastoma.
methodsPreoperatively, 50 patients with neuropathologically confirmed glioblastoma underwent O-(2-[
resultsIn 43 patients (86%), the FET tumour volume was significantly larger than the CE volume (21.5 ± 14.3 mL vs. 9.4 ± 11.3 mL; P < 0.001). Forty patients (80%) showed both increased uptake of FET and CE. In these 40 patients, the spatial similarity between FET uptake and CE was low (mean DSC 0.39 ± 0.21, mean JSC 0.26 ± 0.16). Ten patients (20%) showed no CE, and one of these patients showed no FET uptake. In five patients (10%), increased FET uptake was present outside areas of FLAIR hyperintensity.
conclusionOur results show that the metabolically active tumour volume delineated by FET PET is significantly larger than tumour volume delineated by CE. Furthermore, the results strongly suggest that the information derived from both imaging modalities should be integrated into the management of patients with newly diagnosed glioblastoma.
Indexed as
Identifiers
30327856What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.